---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000008"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:32:52.754253+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Supernus Q4/FY2022: total rev $667.2M (+15% YoY); Qelbree sales $61.3M; FY2023 rev guidance $580-620M

## Summary
- Full year 2022 total revenues $667.2M (+15% YoY); Q4 net product sales $163.8M (+6% vs Q4 2021).
- Qelbree net sales $61.3M in FY2022 (vs $9.9M in FY2021); GOCOVRI $104.4M (+19% vs FY2021).
- GAAP diluted EPS $1.04 for FY2022 (Q4: $0.43); non-GAAP operating earnings $148.8M.
- FY2023 revenue guidance $580-620M (excl. Trokendi XR), ~30% growth; non-GAAP op earnings $65-95M.
- Cash $555.2M at Dec 2022; $150M credit line from UBS; SPN-830 FDA meeting April 2023; SPN-820 Phase II ongoing.

## SEC filing metadata
- accession: 0001356576-23-000008
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/0001356576-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/supn-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000008
- JSON: https://secwatch.observer/filing/0001356576-23-000008.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000008.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported the full year ended December 31, 2022 results: revenue $667.2 million. Guidance initiated.
  - Period: the full year ended December 31, 2022
  - Revenue: $667.2 million
  - Guidance: initiated
  - Result: reported results
  source text: Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/0001356576-23-000008-index.htm
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. updated its the fourth quarter ended December 31, 2022 guidance (initiated).
  - Period: the fourth quarter ended December 31, 2022
  - Guidance: initiated
  - Result: reported results
  source text: On February 28, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/0001356576-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.